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INTRODUCTION
Breast cancer encompasses a heterogeneous population of 
tumors characterized by a variety of clinical, pathological, and 
molecular features [1-3]. Molecular markers such as estrogen 
receptor (ER), progesterone receptor (PR), and human epider-
mal growth factor receptor-2 (HER2) have been used to clas-
sify patients into different subtypes. Recently, gene expression 
studies using DNA microarrays have identified five common 
subtypes of breast cancer: luminal A (ER or PR positive and 
HER2 negative), luminal B (ER or PR positive and HER2 pos-
itive), HER2 overexpressing (ER and PR negative and HER2 
positive), basal-like (ER, PR, and HER2 negative, CK 5/6 posi-
tive) and normal breast-like tumor [2,4-6]. HER2 overexpress-
ing and basal-like subtypes are significantly more likely to be 
grade 3 and are associated with worse recurrence rates and de-
creased overall survival [3,5-7]. The triple negative (TN) phe-
notype, which includes tumors that do not express ER, PR, or 
HER2 on immunohistochemistry (IHC), serves as a proxy for 
the basal-like subtype with a positive predictive value of ap-
proximately 80-97% [8,9]. Although this approach is not com-
plete, several groups have adopted a TN definition for basal-
like cancer out of convenience. 
Several randomized trials have demonstrated that survival 
rates following breast-conserving treatment (BCT) were equiv-
alent to those observed with radical mastectomy [10-12]. Giv-
en these results, BCT has become an accepted treatment for 
early stage breast cancer [13]. At the present time, there is little 
clinical data evaluating whether a particular breast cancer 
subtype is associated with increased rates of local and/or dis-
tant recurrence after BCT [14-17].
The purpose of this study is to determine whether any par-
ticular breast cancer subtype, as approximated by ER, PR, and 
HER2, is associated with patterns of recurrence among wom-
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Purpose: To study clinical features and patterns of recurrence after 
breast-conserving treatment (BCT) for three molecular subtypes 
of early stage breast cancer. Methods: The sample studied in-
cluded 596 patients with T1-2N0-1 breast cancer who received 
BCT. Three groups were defined by receptor status. Luminal: es-
trogen receptor (ER) or progesterone receptor (PR) positive; triple 
negative (TN): ER, PR, and epidermal growth factor receptor-2 
(HER2) receptor negative; and HER2 overexpressing: ER and   
PR negative but HER2 receptor positive. Results: The number of 
patients in each group was 408 (68.5%), 105 (17.6%), and 83 
(13.9%), respectively. The median follow-up period was 79 
months. The TN and HER2 subtypes occurred in younger pa-
tients (p=0.0007) and had higher nuclear grade and poorer his-
tologic grade (p<0.0001 and 0.0071, respectively). During the 
follow-up period, locoregional recurrence was detected as the 
first site of recurrence in 26 (6.4%), 11 (10.5%), and 9 (10.8%) 
patients in the luminal, TN, and HER2 subtypes, respectively (p= 
0.1924). Thirty-one (7.6%), 7 (6.7%), and 7 (8.4%) patients in each 
group had distant metastases as the first sign of recurrence (p= 
0.8996). Median time to locoregional and distant recurrence was 
shorter in the HER2 subtype (p=0.0889 and 0.0780, respective-
ly), and the HER2 subtype was significantly associated with poor 
overall survival (p=0.0009). Conclusion: After BCT in Korean women 
with early stage breast cancer, the patterns of recurrence were 
not different among the molecular subtypes, although the TN and 
HER2 subtypes were associated with younger age, higher nuclear 
grade, and poorer histologic grade. 
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en with early stage breast cancer who receive BCT.
METHODS
Between September 1994 and December 2002, 1,537 pa-
tients with pathologic stage I-III breast cancer according to 
the American Joint Committee on Cancer stages were treated 
with curative surgery without neoadjuvant chemotherapy at 
Samsung Medical Center. All patients had available ER, PR, 
and HER2 receptor status. Medical records were retrospective-
ly reviewed to find patients with pathologic T1-2N0-1 stage 
who received BCT. The number of eligible patients was 596. 
Patients were classified according to the receptor status: lu-
minal (ER or PR positive), TN (ER, PR, and HER2 negative), 
and HER2 (ER, PR negative, and HER2 positive). ER and PR 
status was determined on the basis of IHC staining. Positive 
HER2 was determined using either IHC 3+ staining or ampli-
fication on fluorescence in situ hybridization (FISH).
The median follow-up duration, calculated from the date of 
surgery, was 79 months (range, 5 to 147 months). ANOVA and 
chi-square tests were used to compare the differences in pa-
tient characteristics among the three groups. The endpoints of 
the study were locoregional or distant recurrence as the first 
event, overall survival (OS), and disease-free survival (DFS). 
OS was defined as the time from the date of surgery to death 
from any cause, and DFS was defined as the time from the date 
of surgery to relapse or death. Kaplan-Meier analyses for OS 
and DFS were estimated for each group and compared using 
the log-rank test. Cox proportional hazards regression analy-
sis was used for multivariate analysis. The SAS software (SAS 
9.0; SAS Institute Inc., Cary, USA) was used for statistical anal-
ysis. A probability value of less than 0.05 was considered sta-
tistically significant.
RESULTS
 Among the 596 eligible patients, 391 (65.6%), 298 (50.0%), 
and 297 (49.8%) patients showed positive immunoreactivity 
for ER, PR, and HER2, respectively. As a result, 408 (68.5%), 
105 (17.6%), and 83 (13.9%) patients were classified into the 
luminal, TN, and HER2 overexpressing groups, respectively. 
The characteristics of the patients in each subgroup are outlined 
in Table 1. The TN and HER2 subtypes occurred in younger 
patients (p=0.0007) and were more frequently of a higher nu-
clear grade and poorer histologic grade (p<0.0001 and 0.0071, 
respectively). There were also significant differences in the dis-
tribution of T stage (p=0.0181) and the extensive intraductal 
component (p=0.0119). The distribution of N stage, the over-
all pathologic stage, lymphovascular invasion (LVI), and resec-
tion margin was not different between the three subtypes.
All eligible patients underwent BCT and postoperative whole 
breast radiotherapy. The most common dose delivered was 50.4 
Gy in 28 fractions (555 patients, 93.1%). The primary tumor 
bed was boosted in 538 (90.3%) patients with the most com-
mon dose being 10 Gy in 5 fractions (472 patients, 87.7%). A 
separate supraclavicular or axillary field was not added. Adju-
vant systemic chemotherapy was delivered to 417 (70.0%) pa-
tients and the most common regimen was a combination of 
cyclophosphamide, methotrexate, and 5-fluorouracil (357 pa-
tients, 85.6%, Table 2). Among ER or PR positive patients, 
82.3% (336 of 408) received hormonal therapy (Table 2). No 
patients received adjuvant trastuzumab therapy.
During the follow-up period, there were 26 (6.4%), 11 (10.5 
%), and 9 (10.8%) patients in each group who experienced loco-
regional recurrence as the first site of recurrence (p=0.1924) 
(Table 3). The 5-year cumulative incidence of locoregional re-
currence was 4.1%, 7.0%, and 10.1%, respectively (p=0.1510) 
Table 1. Patient characteristics by receptor status
Luminal  
No. (%)
Triple  
negative  
No. (%)
HER2 over-
expression  
No. (%)
p-value
No. of patients 408 (68.5) 105 (17.6) 83 (13.9)
Median follow-up 79 73 84 0.0137
Median age 46 42 43 0.0007
pT-stage
   1
   2
 
321 (78.7)
  87 (21.3)
 
  70 (66.7)
  35 (33.3)
 
58 (69.9)
25 (30.1)
0.0181
pN-stage
   0
   1
 
325 (79.7)
  83 (20.3)
 
  80 (76.2)
  25 (23.8)
 
69 (83.1)
14 (16.9)
0.5003
Pathologic stage
   I
   IIA
   IIB
 
254 (62.3)
138 (33.8)
16 (3.9)
 
  54 (51.4)
  42 (40.0)
  9 (8.6)
 
49 (59.1)
29 (34.9)
5 (6.0)
0.1758
Nuclear grade
   Low
   Intermediate
   High
   Unknown
 
  67 (16.4)
216 (53.0)
  76 (18.6)
  49 (12.0)
 
  3 (2.9)
  22 (20.9)
  69 (65.7)
  11 (10.5)
 
5 (6.0)
24 (28.9)
48 (57.9)
6 (7.2)
<0.0001
Histologic grade
   Well
   Moderate
   Poor
   Unknown
 
39 (9.6)
213 (52.2)
  52 (12.7)
104 (25.5)
 
  3 (2.9)
  64 (60.9)
  25 (23.8)
  13 (12.4)
 
6 (7.2)
33 (39.8)
18 (21.7)
26 (31.3)
0.0071
EIC
   Yes
   No
 
100 (24.5)
308 (75.5)
 
  13 (12.4)
  92 (87.6)
 
24 (28.9)
59 (71.1)
0.0119
LVI
   Yes
   No
33 (8.1)
375 (91.9)
  9 (8.6)
  96 (91.4)
  9 (10.8)
74 (89.2)
0.6691
Resection margin
   Negative
   Positive
 
392 (96.1)
16 (3.9)
 
102 (97.1)
  3 (2.9)
 
80 (96.4)
3 (3.6)
0.8747
HER2=human epidermal growth factor receptor 2; EIC=extensive intraductal 
component; LVI=lymphovascular invasion.48   Jae Myoung Noh, et al.
http://ejbc.kr  DOI: 10.4048/jbc.2011.14.1.46
(Figure 1). Median time to locoregional recurrence was 50.5, 40, 
and 28 months in each group, respectively (p=0.0889). The 
local area of the original tumor was the most frequent site of 
locoregional recurrence among the luminal (18 patients, 69.2%) 
and HER2 (8 patients, 88.9%) subtypes. Among the patients in 
the TN group, the supraclavicular area was the most frequent 
site (6 patients, 54.5%). Distant metastasis as the first site of 
recurrence occurred in 31 (7.6%) patients with the luminal 
subtype after a median time of 38 months. The median time 
to distant recurrence of TN and HER2 subtype was 26 and 21 
months, respectively (p=0.0780). The overall incidence of 
distant recurrence during the follow-up period was 6.7% and 
8.4% in the TN and HER2 subtypes, respectively (p=0.8996). 
The 5-years cumulative incidence of distant recurrence was 
6.0%, 5.9%, and 8.6%, respectively (p=0.9348)(Figure 2). 
The 5-years OS and DFS rates of all patients were 95.4% and 
89.7%, respectively. OS of the HER2 subtype was significantly 
poorer than other subtypes in univariate analysis (p=0.0009). 
The 5-year OS rate of each subtype was 97.4%, 94.9%, and 86.4%, 
respectively (Figure 3). DFS was not significantly different be-
tween the three subtypes (p=0.3862)(Figure 4). By multivari-
ate Cox proportional hazard models, tumor subtype, nuclear 
grade, and histologic grade were significant prognostic factors 
affecting OS (Table 4). The hazard ratio of the TN and HER2 
subtypes were 1.63 (95% confidence interval [CI], 0.46-5.73; 
p=0.4461) and 2.43 (95% CI, 1.44-4.09; p=0.0009), respec-
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Figure 1. Cumulative incidence of locoregional recurrence as the first 
event.
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Figure 2. Cumulative incidence of distant metastasis as the first site of 
recurrence.
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Table 2. Adjuvant systemic treatment by receptor status
Luminal  
No. (%)
Triple negative 
No. (%)
HER2 over- 
expression  
No. (%)
Chemotherapy
   CMF
   AC
   No
 
222 (54.4)
  41 (10.1)
145 (35.5)
 
  80 (76.2)
  15 (14.3)
10 (9.5)
 
55 (66.3)
4 (4.8)
24 (28.9)
Hormonal therapy
   Tamoxifen
   Toremifen
   No
 
288 (70.6)
  48 (11.8)
  72 (17.6)
 
  2 (1.9)
0
103 (98.1)
 
1 (1.2)
1 (1.2)
81 (97.6)
HER2=human epidermal growth factor receptor-2; CMF=cyclophosphamide
+methotrexate+5-fluorouracil; AC=adriamycin+cyclophosphamide.
Table 3. Patterns of first recurrence according to tumor subtype
Recurrence pattern
Tumor subtype
p-value Luminal  
No. (%)
Triple  
negative  
No. (%)
HER2  
No. (%)
Locoregional
   Breast+Chest wall
   Axilla
   Supraclavicular
   Contralateral
26 (6.4)
  18 (69.2)
  1 (3.8)
    6 (23.1)
  1 (3.8)
11 (10.5)
  3 (27.3)
1 (9.1)
  6 (54.5)
1 (9.1)
  9 (10.8)
  8 (88.9)
  1 (11.1)
  1 (11.1)
0
0.1924
Distant
   Bone
   Lung
   Liver
   Brain
   Others
31 (7.6)
  14 (45.2)
  13 (41.9)
    4 (12.9)
  2 (6.5)
    4 (12.9)
7 (6.7)
  3 (42.9)
  3 (42.9)
0
  2 (28.6)
  2 (28.6)
7 (8.4)
  4 (57.1)
  3 (42.9)
  3 (42.9)
0
0
0.8996
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Figure 3. Overall survival after breast-conserving treatment for early 
stage breast cancer.
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tively. LVI, nuclear and histologic grade significantly affected 
DFS.
DISCUSSION
In this series, the recurrence patterns of 596 patients with 
conservatively-treated early breast cancer were evaluated based 
on ER, PR, and HER2 expression status. Although negative 
expression for the three markers has previously been used to 
categorize tumors such as basal-like cancer, the incomplete-
ness of the definition is a potential weakness of this study [1,3-
6]. This study was also limited due to its retrospective analysis, 
relatively small sample size in the HER2 and TN subgroups, 
and potential existence of other variables. Because no patient 
received trastuzumab therapy, the results could be changed by 
trastuzumab therapy. During the follow-up period, overall in-
cidence of locoregional and distant recurrence as first site of 
recurrence was not significantly different between subgroups. 
Although not statistically significant, the time to recurrence in 
the HER2 subtype was shorter than that of other subtypes.
Nguyen et al. [15] reported a series of 793 patients with inva-
sive breast cancer who received BCT. Based on the three mark-
ers, patients were categorized into four groups: luminal A and 
B, basal, and HER2. The basal and HER2 subtypes were associ-
ated with younger patients, higher grade tumors, and increased 
risk of local recurrence. The median age of the TN and HER2 
subtypes was 51 and 49 years, respectively. The two subtypes 
were also associated with an increased risk of distant metasta-
ses than seen in the luminal A subtype. In this series, the TN 
and HER2 subtypes were also associated younger age and high-
er grade. But there were two differences between the two ser-
ies. First, the median age of the TN and HER2 subtypes in the 
current series was 42 and 43 years, respectively, which was rela-
tively younger than that of the other series. Second, an increased 
risk of local or distant recurrence was not seen in the present 
study. But the 5-year cumulative incidence of locoregional re-
currence in luminal subgroup was 4.1%, which was relatively 
higher than that of the luminal A and B group in the other se-
ries (0.8% and 1.5%, respectively). The incidence of the TN 
and HER2 groups did not differ much from each other (7.0% 
and 10.1% vs. 7.1% and 8.4%, respectively).
Two additional studies showed that the TN or HER2 sub-
types do not appear to be at a significantly increased risk for 
local or locoregional recurrence [16,17]. In the series of Dent 
et al. [16], the mean age was significantly younger for the TN 
group compared with the other group (53.0 vs. 57.7 years, p< 
0.0001). Also, patients in the TN group were more likely to 
have grade III tumors (66% vs. 28%, p<0.0001) that were larg-
er. Despite such different characteristics, the TN subtype had 
a similar overall local recurrence rate to that of other subtypes 
of breast cancer (13% vs. 12%, p=0.77), but the mean time to 
local recurrence was shorter in patients with the TN subtype 
(2.8 vs. 4.2 years, p=0.02). The median time to distant recur-
rence was also shorter in the TN group (2.6 vs. 5.0 years, p< 
Table 4. Cox proportional hazards multivariate model for overall (OS) and disease-free survival (DFS)
Variable
OS DFS
HR 95% CI p-value HR 95% CI p-value
Tumor subtype 0.0106 0.8315
   TN vs. Luminal 1.63 0.46-5.73 0.4461 0.98 0.48-2.00 0.9531
   HER2 vs. Luminal 2.43 1.44-4.09 0.0009 0.94 0.64-1.39 0.7698
Age (<45 yr vs. ≥45 yr) 0.75 0.31-1.82 0.5265 0.86 0.50-1.48 0.5837
LVI 0.85 0.24-3.01 0.7950 0.40 0.21-0.77 0.0064
EIC 1.42 0.51-3.94 0.5060 1.24 0.64-2.39 0.5270
Nuclear grade 2.81 1.25-6.28 0.0121 1.98 1.23-3.17 0.0050
Histologic grade 2.28 1.06-4.90 0.0343 1.69 1.04-2.76 0.0345
Pathologic T stage 0.84 0.31-2.31 0.7370 0.81 0.42-1.57 0.5380
Pathologic N Stage 1.28 0.50-3.25 0.6099 1.32 0.74-2.35 0.3440
HR=hazard ratio; CI=confidence interval; TN=triple negative; HER2=human epidermal growth factor receptor-2; LVI=lymphovascular invasion; EIC=extensive in-
traductal component.
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Figure 4. Disease free survival after breast-conserving treatment for 
early stage breast cancer.
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0.0001) and the proportion of patients with distant recurrence 
was higher in the TN subtype (33.9% vs. 20.4%, p<0.0001). 
The trend of shorter disease-free interval could be found in the 
HER2 subtype of our series, although the p-value was not sta-
tistically significant.
Freedman et al. [17] defined three groups similar to the cur-
rent series: ER or PR (+), HER2, and TN. As was seen in the 
present study, patients in the TN and HER2 groups were more 
likely to have T2 and grade 3 diseases. The median age of the 
TN and HER2 groups was both 54 years, which was also older 
than that of the present study. They also reported that there was 
no overall difference in total locoregional recurrence rates be-
tween the three groups (p=0.13). Additionally, a higher rate 
of distant metastases in the HER2 group was observed (11.9%, 
p=0.009) which translated into a lower recurrence-free sur-
vival rate (84%, p=0.005).
The major difference between the current series and those 
reported previously is that there were no significant differences 
in overall incidence of distant metastases between the three 
groups during the follow-up period. Because the first site of 
recurrence was selected as an end point and included early 
stage patients who received BCT into analysis, the incidence 
of distant metastases could increase by the addition of patients 
who experienced local recurrence first followed by distant re-
currence and who had more advanced disease. DFS was not 
significantly different between the three subtypes, but OS rate 
of the HER2 group was decreased compared to that of the oth-
er groups (p=0.0009).
In addition, the age distribution of the current series was rel-
atively younger than that of the others. It has been known that 
the age distribution of breast cancer incidence in Korea is dif-
ferent from that in the United States and in other Western 
countries [18,19]. The peak age of incidence is younger in Ko-
rea, which was also shown in this series. Despite the retro-
spective nature with relatively small number of patients, the 
recurrent patterns after BCT according to molecular subtype 
in Korean patients with relatively younger age are remarkable 
feature of this study.
Having the HER2 subtype of tumor seems to carry a worse 
prognosis; however, the use of adjuvant trastuzumab, a human-
ized monoclonal antibody directed against HER2, could im-
prove the clinical outcomes in the HER2 overexpressing sub-
type [20,21]. Two large randomized trials reported the benefit 
of adjuvant trastuzumab. In the Herceptin Adjuvant (HERA) 
trial, the unadjusted hazard ratio for the risk of an event in the 
trastuzumab group was 0.54 (95% CI, 0.43-0.67; p<0.0001), 
which corresponded to an absolute benefit of 8.4% in disease-
free survival at 2 years [20]. The National Surgical Adjuvant 
Breast and Bowel Project (NSABP) B-31 trial and the North 
Central Cancer Treatment Group (NCCTG) N9831 trial 
showed a hazard ratio of 0.48 for a first event in the trastu-
zumab group (95% CI, 0.39-0.59, p<0.0001). The absolute 
benefit in DFS was 11.8% at 2 years [21].
Because of their lack of receptors for ER, PR, and HER2, those 
patients with TN breast cancer are not candidates for adjuvant 
hormonal therapy or trastuzumab. However, they may be can-
didates for targeted antibodies against epidermal growth factor 
receptor (EGFR) because basal-like tumors have been shown 
to overexpress EGFR [8,22,23]. Future studies are needed to 
establish the role of novel targeted treatments in patients with 
TN and HER2 breast cancer. 
In summary, the TN and HER2 breast cancer occurred in 
younger patients and were more likely to have high grade tu-
mors. The HER2 subtype was significantly associated with poor 
OS, but there was no difference in patterns of recurrence ac-
cording to molecular subtypes among women with early stage 
breast cancer who had received BCT. 
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